Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Stopped Early signs of progression and learned experience that the assumed time period between psa progression and radiographic progression was shorter than expected

Conditions

• Metastatic Castration-resistant Prostate Cancer

Interventions

• DRUG: Avelumab
• DRUG: 2nd generation ADT (abiraterone or enzalutamide)

Sponsor

Jodi Layton, MD

Collaborators

• [object Object]